FDA Approves Emergency Use of COVID-19 Vaccine

FDA Approves Emergency Use of COVID-19 Vaccine

December 11 the U.S. Food and Drug Administration (FDA) announced the first emergency use authorization (EUA) for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. The EUA allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The vaccine is being allocated based on each state’s adult population. Health care personnel and residents of long-term care facilities will be offered vaccination in the COVID-19 vaccination program’s initial phase, followed by workers in essential and critical industries.

Additionally, the CDC’s Advisory Committee on Immunization Practices (ACIP) issued an Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine for all persons over 16 years old on December 12. The vaccine’s initial delivery is expected to be completed in all 50 states by December 16, comprising 2.9 million doses of the Pfizer vaccine.

Another vaccine being developed by Moderna is expected to receive emergency authorization by the FDA shortly.

IWLA Member

To become an IWLA member visit,
http://31y.93c.myftpupload.com/become-an-iwla-member/